Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: Identification of a new gene signature for prognostic evaluation in cervical cancer: based on cuproptosis-associated angiogenesis and multi-omics analysis

Fig. 6

Drug sensitivity analysis of the high and low-CuRA group. (A-I) The IC50 of Imatinib, Pazopanib, and Sorafenib was lower in the high-CuRA group than for the low-CuRA group contrary to AMG.706, CEP.701, Sunitinib, ABT.888, AZD.2281, and MS.275. The vertical coordinates displayed as drug names, demonstration of drugs with statistical significance

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us